NASDAQ:AGRXAgile Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Agile Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.70 +0.01 (+0.37 %) (As of 08/11/2020 11:58 AM ET) Add Compare Share Today's Range$2.63Now: $2.70▼$2.7250-Day Range$2.37MA: $2.64▼$2.9852-Week Range$0.35Now: $2.70▼$4.77Volume12,305 shsAverage Volume970,366 shsMarket Capitalization$235.47 millionP/E RatioN/ADividend YieldN/ABeta1.38 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAgile Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.50, Agile Therapeutics has a potential upside of 144.4% from its current price of $2.66.Amount of Analyst CoverageAgile Therapeutics has received no research coverage in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesAgile Therapeutics has received 397 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAgile Therapeutics has received 253 “underperform” votes. (Add your “underperform” vote.)Community SentimentAgile Therapeutics has received 61.08% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote “Outperform” if you believe AGRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAgile Therapeutics does not currently pay a dividend.Dividend GrowthAgile Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agile Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of Agile Therapeutics is held by insiders.Percentage Held by Institutions37.87% of the stock of Agile Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Agile Therapeutics are expected to grow in the coming year, from ($0.59) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agile Therapeutics is -7.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agile Therapeutics is -7.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgile Therapeutics has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.63 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGRX Previous Symbol CUSIPN/A CIK1261249 Webwww.agiletherapeutics.com Phone609-683-1880Debt Debt-to-Equity Ratio0.17 Current Ratio33.69 Quick Ratio33.69Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book3.51Profitability EPS (Most Recent Fiscal Year)($0.38) Net Income$-18,610,000.00 Net MarginsN/A Return on Equity-45.62% Return on Assets-40.19%Miscellaneous Employees13 Outstanding Shares87,210,000Market Cap$235.47 million Next Earnings Date8/11/2020 (Confirmed) OptionableOptionable $2.70 +0.01 (+0.37 %) (As of 08/11/2020 11:58 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AGRX News and Ratings via Email Sign-up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter. Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions How has Agile Therapeutics' stock been impacted by Coronavirus (COVID-19)? Agile Therapeutics' stock was trading at $1.94 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AGRX stock has increased by 39.2% and is now trading at $2.70. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Agile Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agile Therapeutics. When is Agile Therapeutics' next earnings date? Agile Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Agile Therapeutics. How were Agile Therapeutics' earnings last quarter? Agile Therapeutics Inc (NASDAQ:AGRX) announced its quarterly earnings results on Tuesday, May, 5th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01. View Agile Therapeutics' earnings history. What price target have analysts set for AGRX? 5 brokers have issued twelve-month price targets for Agile Therapeutics' shares. Their forecasts range from $3.00 to $9.00. On average, they expect Agile Therapeutics' share price to reach $6.50 in the next twelve months. This suggests a possible upside of 140.7% from the stock's current price. View analysts' price targets for Agile Therapeutics. Has Agile Therapeutics been receiving favorable news coverage? Media headlines about AGRX stock have trended neutral on Tuesday, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Agile Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Agile Therapeutics. Are investors shorting Agile Therapeutics? Agile Therapeutics saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 4,250,000 shares, an increase of 21.4% from the January 31st total of 3,500,000 shares. Based on an average daily trading volume, of 3,410,000 shares, the short-interest ratio is currently 1.2 days. View Agile Therapeutics' Short Interest. Who are some of Agile Therapeutics' key competitors? Some companies that are related to Agile Therapeutics include VBI Vaccines (VBIV), Generation Bio (GBIO), Legend Biotech (PLRX), DiaMedica Therapeutics (DMCAF), Gossamer Bio (GOSS), Morphic (MORF), BioXcel Therapeutics (BTAI), Cara Therapeutics (CARA), Repare Therapeutics (RPTX), Rhythm Pharmaceuticals (RYTM), Phibro Animal Health (PAHC), Dynavax Technologies (DVAX), ORIC Pharmaceuticals (ORIC), Endo International (ENDP) and ZIOPHARM Oncology (ZIOP). View all competitors. What other stocks do shareholders of Agile Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include Opko Health (OPK), Amarin (AMRN), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Nabriva Therapeutics (NBRV), Inovio Pharmaceuticals (INO), AcelRx Pharmaceuticals (ACRX), Novavax (NVAX) and Viking Therapeutics (VKTX). Who are Agile Therapeutics' key executives? Agile Therapeutics' management team includes the following people: Mr. Alfred F. Altomari, Chairman & CEO (Age 60)Mr. Scott M. Coiante, CFO & Sr. VP (Age 52)Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 51)Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 53)Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 62) What is Agile Therapeutics' stock symbol? Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX." Who are Agile Therapeutics' major shareholders? Agile Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include SG Americas Securities LLC (0.28%), Premier Asset Management LLC (0.13%), Dumont & Blake Investment Advisors LLC (0.10%), New York State Common Retirement Fund (0.07%), Principal Financial Group Inc. (0.03%) and State Board of Administration of Florida Retirement System (0.03%). Company insiders that own Agile Therapeutics stock include Abhijeet J Lele, Alfred Altomari, Dennis Reilly, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View institutional ownership trends for Agile Therapeutics. Which institutional investors are buying Agile Therapeutics stock? AGRX stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, New York State Common Retirement Fund, Principal Financial Group Inc., Dumont & Blake Investment Advisors LLC, State Board of Administration of Florida Retirement System, UBS Group AG, Comerica Bank, and Amalgamated Bank. Company insiders that have bought Agile Therapeutics stock in the last two years include Abhijeet J Lele, Alfred Altomari, Dennis Reilly, Life Sciences Maste Perceptive, and Perceptive Advisors Llc. View insider buying and selling activity for Agile Therapeutics. How do I buy shares of Agile Therapeutics? Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Agile Therapeutics' stock price today? One share of AGRX stock can currently be purchased for approximately $2.70. How big of a company is Agile Therapeutics? Agile Therapeutics has a market capitalization of $235.47 million. The specialty pharmaceutical company earns $-18,610,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Agile Therapeutics employs 13 workers across the globe. What is Agile Therapeutics' official website? The official website for Agile Therapeutics is www.agiletherapeutics.com. How can I contact Agile Therapeutics? Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
